Herbst, R., Marinis, F. D., Giaccone, G., Reinmuth, N., Vergnenegre, A., Barrios, C., Morise, M., Font, E., Andric, Z., Geater, S., Ozguroglu, M., Mocci, S., McCleland, M., Enquist, I., Komatsubara, K., Deng, Y., Kuriki, H., Wen, X., Jassem, J., & Spigel, D. (n.d.). o81 IMpower110: interim overall survival (OS) analysis of a phase III study of atezolizumab (ATEZO) monotherapy vs platinum-based chemotherapy (CHEMO) as first-line (1L) treatment in PD-L1–selected NSCLC. Journal for immunotherapy of cancer, 8, A1. http://access.bl.uk/ark:/81055/vdc_100135177555.0x000006